Table 4.
Summary of results for IFN-γ release ELISpot for patients and tolerant controls
| Result of IFN-γ release ELISpot | Patients | Tolerant controls, n = 16 |
|||||
|---|---|---|---|---|---|---|---|
| SJS/TEN, n = 4 | DRESS, n = 14 | AGEP, n = 1 | Acute patientsa, n = 4 | Convalescent patientsb, n = 15 | All patients, n = 19 | ||
| Positive | 2 (50) | 8 (57) | 0 (0) | 3 (75) | 7 (47) | 10 (53) | 0 (0) |
| Negative | 1 (25) | 6 (43) | 1 | 1 (25) | 7 (47) | 8 (42) | 16 (100) |
| Indeterminatec | 1 (25) | 0 (0) | 0 (0) | 0 (0) | 1 (7) | 1 (5) | 0 (0) |
Values are given as No. (%)
Abbreviations: SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS, drug reaction with eosinophilia and systemic symptoms; AGEP, acute generalized exanthematous pustulosis.
a
Acute patients were defined as within 6 weeks of SCAR onset
b
Convalescent patients were defined as > 6 weeks’ post SCAR onset
c
In an indeterminate results being the CD3 response was not present; this was included in analysis as a ‘false negative’.